The Jewish General Hospital is pleased to announce that Dr. Gerald Batist has been re-appointed Chair of the Department of Oncology for a third term. The Search and Selection Committee noted that the Department has “flourished under Dr. Batist’s tenure,” securing a national and international reputation for clinical care and for fundamental and translational research, concluding that “he is the best person to lead the Department of Oncology going forward.”
Dr. Batist is a medical oncologist and molecular pharmacologist, whose research focuses on novel drug development and therapeutic resistance. He is the Director of the Segal Cancer Center, and Deputy Director and leader of the Cancer Axis at the Lady Davis Institute. He is a tenured Professor of Oncology at McGill and was the University’s Chair of Oncology for 10 years. He co-created the Quebec Clinical Research Organization in Cancer (Q-CROC), a province-wide network, and was a co-founder the Worldwide Innovative Networking (WIN) consortium for personalized cancer medicine, which is based in Paris. He has published over 200 papers and book chapters, and shares multiple patents for new chemical entities with novel therapeutic potential. Dr. Batist has achieved significant funding for personalized medicine initiatives, leading large groups in biopsy-driven innovative studies designed to identify molecular signatures of resistance and novel therapeutic targets.